Anti-Cancer Drug Market

Anti-Cancer Drug Market by Treatment Types (Hormone Therapy, Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, and Stem Cell Transplant) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028

  • Report ID: HC-2601
  • Author: Growth Market Reports
  • Rating: 4.2
  • Total Reviews: 3
  • No. Of Pages: 210
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global anti-cancer drug market size is estimated to register a significant CAGR during the forecast period, 2021-2028. The growth of the market is attributed to the increasing incidence of cancer across the globe. The further growth of the market is attributed to the approval of new drugs by the regional regulatory bodies coupled with the support provided by the non-profit organizations and the regional government.

Anti-Cancer Drug Market

Drugs that block the growth of cancer and prevent them from further expansion are known as anti-cancer drugs. These drugs are effective in the treatment of cancerous diseases. Across the globe, the most common type of cancer among men is lung cancer and breast cancer among women. As per the fact sheet by Globocan 2020, approximately 19,292,789 new cancer cases were diagnosed along with 9,958,133 deaths caused by cancer, worldwide. Another report by the International Agency for Research on Cancer (IARC) states that globally the total sum of cancer cases is expected to reach 27.5 million along with 16.3 million deaths caused due to cancer.

The COVID-19 pandemic has significantly affected several industries across the globe and it has a negative impact on anti-cancer drug market. Reports suggest that there is a decrease in the rate of diagnosis of most common types of cancer that include gastric cancer, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, and esophageal cancer. Cancer screenings and surgeries related to cancer were also postponed in order to prevent the spreading risk of COVID-19 and to secure the infrastructure of the hospitals. However, the situation is improving at a gradual pace.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing awareness among the consumers regarding the availability of new drugs for cancer treatment through media channels is anticipated to fuel the market growth during the forecast period.
  • Rising number of patient assistance programs coupled with the growing demand for medicines personalized for individual are expected to propel the market growth.
  • High cost of cancer therapies and issues concerning side effects due to usage of these drugs are key challenges that can restrain the market growth during the forecast period.
  • Lack of well-established reimbursement policies & occurrence of fluctuation in them along with stringent regulations imposed by governments are estimated to hinder the market expansion.
  • Increasing initiatives by several public healthcare-based organizations to increase awareness towards cancer and strong research & development initiatives taken by various pharmaceutical companies for the production of new drugs are projected to create lucrative opportunities for market growth.

Scope of the Report

The report on the global anti-cancer drug market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Anti-Cancer Drug Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Treatment Types (Hormone Therapy, Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, and Stem Cell Transplant)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Teva Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Bayer; Novartis; Pfizer; Sanofi; Amgen; Ariad Pharmaceuticals; Celgene Corp.;  Eli Lilly; AstraZeneca; Hoffmann-La Roche Ltd.; Boehringer Ingelheim GmbH; Sun pharmaceutical; and Merck

Market Segment Insights

Hormone therapy segment is expected to grow at a lucrative rate

On the basis of treatment types, the global anti-cancer drug market is divided into hormone therapy, surgery, immunotherapy, radiation therapy, chemotherapy, and stem cell transplant. The hormone therapy segment is expected to grow at a lucrative rate during the forecast period owing to increasing approvals of products and rising research activities related to hormone therapy. Hormone therapy is a type of targeted therapy that is used for the treatment of cancer in which the specific gene or proteins present in the cancer cells are targeted by using drugs. Several drugs and therapies were approved recently for the treatment of cancer. For instance, Trastuzumab also known as Herceptin was approved for the treatment of stomach and breast cancer. Trodelvy was approved for the treatment of adult patients suffering from triple-negative breast cancer. Tabrecta, also known as capmatinib, was approved for the treatment of non-small cell lung cancer.

Anti-Cancer Drug Market

Asia Pacific is anticipated to have a considerable market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a large share of the market in 2020 and is projected to exhibit a high CAGR during the forecast period due to the availability of developed healthcare industry, advancements in the development of new drug, and growing government initiatives to increase the level of awareness among consumers in the region. North America was followed by Europe that held a key share of the market. However, the market of Asia Pacific is anticipated to have a considerable market share during the forecast period owing to improvements made in the healthcare infrastructure in the region.

Anti-Cancer Drug Market

Segments

The global anti-cancer drug market has been segmented on the basis of

Treatment Types

  • Hormone Therapy
  • Surgery
  • Immunotherapy
  • Radiation Therapy
  • Chemotherapy
  • Stem Cell Transplant

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Teva Pharmaceuticals
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Bayer
  • Novartis
  • Pfizer
  • Sanofi
  • Amgen
  • Ariad Pharmaceuticals
  • Celgene Corp.
  • Eli Lilly
  • AstraZeneca
  • Hoffmann-La Roche Ltd.
  • Boehringer Ingelheim GmbH
  • Sun pharmaceutical
  • Merck

Competitive Landscape

Key players competing in the global anti-cancer drug market are Teva Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Bayer; Novartis; Pfizer; Sanofi; Amgen; Ariad Pharmaceuticals; Celgene Corp.; Eli Lilly; AstraZeneca; Hoffmann-La Roche Ltd.; Boehringer Ingelheim GmbH; Sun pharmaceutical; and Merck. Many of these players have adopted business strategies such as launch of new products, advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their consumer base and expand market position globally.

For instance, Allergan and Pfizer merged together on November 23, 2015, which was considered to be the largest pharmaceutical deal ever locked. Another example is that Ranbaxy was acquired by Sun pharmaceutical on April 07, 2014, by which the latter company became the fifth largest pharmaceutical company across the world.

Anti-Cancer Drug Market

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Anti-Cancer Drug Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Anti-Cancer Drug Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Anti-Cancer Drug Market - Supply Chain
  4.5. Global Anti-Cancer Drug Market Forecast
     4.5.1. Anti-Cancer Drug Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Anti-Cancer Drug Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Anti-Cancer Drug Market Absolute $ Opportunity
5. Global Anti-Cancer Drug Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Anti-Cancer Drug Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Anti-Cancer Drug Demand Share Forecast, 2019-2026
6. North America Anti-Cancer Drug Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Anti-Cancer Drug Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Anti-Cancer Drug Demand Share Forecast, 2019-2026
7. Latin America Anti-Cancer Drug Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Anti-Cancer Drug Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Anti-Cancer Drug Demand Share Forecast, 2019-2026
8. Europe Anti-Cancer Drug Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Anti-Cancer Drug Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Anti-Cancer Drug Demand Share Forecast, 2019-2026
9. Asia Pacific Anti-Cancer Drug Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Anti-Cancer Drug Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Anti-Cancer Drug Demand Share Forecast, 2019-2026
10. Middle East & Africa Anti-Cancer Drug Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Anti-Cancer Drug Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Anti-Cancer Drug Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Anti-Cancer Drug Market: Market Share Analysis
  11.2. Anti-Cancer Drug Distributors and Customers
  11.3. Anti-Cancer Drug Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)

The global anti-cancer drug market has been segmented on the basis of

Treatment Types

  • Hormone Therapy
  • Surgery
  • Immunotherapy
  • Radiation Therapy
  • Chemotherapy
  • Stem Cell Transplant

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Teva Pharmaceuticals
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Bayer
  • Novartis
  • Pfizer
  • Sanofi
  • Amgen
  • Ariad Pharmaceuticals
  • Celgene Corp.
  • Eli Lilly
  • AstraZeneca
  • Hoffmann-La Roche Ltd.
  • Boehringer Ingelheim GmbH
  • Sun pharmaceutical
  • Merck

Key players competing in the global anti-cancer drug market are Teva Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Bayer; Novartis; Pfizer; Sanofi; Amgen; Ariad Pharmaceuticals; Celgene Corp.; Eli Lilly; AstraZeneca; Hoffmann-La Roche Ltd.; Boehringer Ingelheim GmbH; Sun pharmaceutical; and Merck. Many of these players have adopted business strategies such as launch of new products, advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their consumer base and expand market position globally.

For instance, Allergan and Pfizer merged together on November 23, 2015, which was considered to be the largest pharmaceutical deal ever locked. Another example is that Ranbaxy was acquired by Sun pharmaceutical on April 07, 2014, by which the latter company became the fifth largest pharmaceutical company across the world.

Anti-Cancer Drug Market

Buy Report